
Opinion|Videos|July 2, 2024
RSV Vaccine Efficacy in Pregnancy
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.
Advertisement
Episodes in this series

- What were the key results from the
MATISSE trial regarding the safety and efficacy of the non-adjuvanted vaccine in pregnant women?- Efficacy in preventing severe RSV in infants
- Adverse effects in maternal and infant subjects
- Trial limitations: no high-risk pregnancies
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC’s Autism Statement Sparks New Concerns Over Vaccine Safety Messaging
2
Patients With Long COVID Face Varying Trajectories, With Most Facing Symptoms Long After Infection
3
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing
4
Billions at Stake: 340B Program Integrity and Sustainability in 2024–2025
5












































































































































































































